There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CytoDyn Inc (CYDY) and Nabriva (NBRV) with bullish sentiments.
CytoDyn Inc (CYDY)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CytoDyn Inc today and set a price target of $1.50. The company’s shares closed yesterday at $0.50.
Selvaraju commented:
“We note that leronlimab is a humanized IgG4 monoclonal antibody that blocks CCR5, which functions in both the progression of cancer metastasis and HIV. Our current valuation of leronlimab does not include its application in cancers. Therefore, positive data in cancer indications could drive additional upside to our price target. In the wake of this update, we reiterate our Buy rating and $1.50 price target. Cytodyn is scheduled to host an investment community conference call on the coming Monday to provide a business update. All combo therapy patients to switch to 700 mg dose. The FDA has recognized that the higher dosage of 700 mg in the monotherapy trial had a much higher response rate than the 350 mg dose used in the combination therapy trial, and has agreed to accept safety data from 100 patients in the monotherapy trial with the 700 mg dose.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.3% and a 32.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on CytoDyn Inc is a Moderate Buy with an average price target of $1.50.
See today’s analyst top recommended stocks >>
Nabriva (NBRV)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Nabriva, with a price target of $9. The company’s shares closed yesterday at $2.05.
Arce commented:
“We note that lefamulin also met EMA’s specified primary endpoints in LEAP 1 and LEAP 2, and therefore we expect Nabriva to report any regulatory update from the EMA regarding lefamulin’s potential approval in the EU as they are available. Affirm Buy and PT of $9. We employ a rNPV valuation model, driven by U.S. sales of: (1) lefamulin for CABP through 2028 (peak sales $460M); and (2) CONTEPO for cUTI through 2028 (peak sales $205M). We utilize a 14.0% discount rate for all cash flows, with zero terminal value after 2028, to arrive at $9 price target (representing risk- adjusted per share values of about $7 for lefamulin and about $2 for CONTEPO).”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.1% and a 38.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nabriva with a $12 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
